Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
• ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapy • AMPLICITY Trial Initiation: The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruit
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- NARMAFOTINIB Large-Scale Manufactre Complete
- ACCENT data presented at 2026 asco gastrointestinal cancer symposium
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
- Additional Confirmed Response Reported as Part of Amplia Investor Presentation
Later from Amplia Therapeutics
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
- Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
- Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
- Pause in Trading
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics